Epratuzumab, a monoclonal antibody against CD22, has shown effectiveness in reducing B cell numbers in patients with SLE without increasing adverse events, suggesting its potential as a novel therapeutic for SS, pending validation through extensive clinical trials (152). Here, CD22 is linked to systemic lupus erythematosus.